Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET
Company Participants
Jason Fredette - Senior Vice President, Investor Relations and Corporate Communications
Anna Protopapas - President, CEO & Director
Arvin Yang - Senior VP & Chief Medical Officer
Brian DeSchuytner - Senior VP & CFO
Conference Call Participants
Jonathan Chang - SVB Securities
Colleen Kusy - Baird
Operator
Good afternoon, and welcome to Mersana Therapeutics Second Quarter 2022 Conference Call and webcast. Currently, all participants are in a listen-only mode. There will be a question answer session at the end of this call.
I would now like to turn the call over to Jason Fredette, Senior Vice President, Investor Relations and Corporate Communications. Please proceed.
Jason Fredette
Good afternoon, everyone. Before we begin, please note that this call will contain forward-looking statements within the meaning of the federal securities laws. These statements may include, but are not limited to, those related to the company's business strategy, platform potential, clinical trial or preclinical study execution and data releases, regulatory plans and objectives, commercial opportunities, collaborations and potential associated payments, operating expenses and cash runway. Each of these forward-looking statements is subject to risks and uncertainties that could cause actual results to differ materially from those projected in such statements.
These risks and uncertainties are discussed in the company's quarterly report on Form 10-Q filed with the Securities and Exchange Commission on May 9, 2022 and in subsequent SEC filings. Our filings are available at sec.gov and on our website, mersana.com. Except as required by law, we assume no obligation to update forward-looking statements publicly even if new information becomes available in the future.
With that, let me turn the call over to Anna Protopapas, our President and Chief Executive Officer.
Anna Protopapas
Hello, everyone, and welcome to
- Read more current MRSN analysis and news
- View all earnings call transcripts